first week of tirzepatide What to Expect: Weight Loss in the FDA approval for Zepbound (tirzepatide)

In a statement, Lilly confirmed that the treatment delivered significant weight loss, meaningful A1C reductions and improvements in cardiometabolic risk factors at 72 weeks

Reduced Reward Sensitivity: By dampening the brain's response to highly rewarding stimuli, GLP-1 RAs might help individuals feel less driven by immediate gratification, which can be beneficial in managing conditions like depression and substance use disorders

not a valid standalone primary diagnosis

so, it banned quinines use for this purpose, in both over-the-counter preparations and even in prescriptions, after receiving hundreds of reports of serious adverse events associated with quinine use, including 93 deaths